Concepedia

Publication | Closed Access

Phase I-II clinical and pharmacologic studies of high-dose cytosine arabinoside in refractory leukemia

DOI

137

Citations

33

References

1986

Year

Hagop M. Kantarjian, Elihu H. Estey, William Plunkett, Michael J. Keating, Ronald S. Walters, Stephen Iacoboni, Kenneth B. McCredie, Emil J. Freireich
The American Journal of Medicine

References

YearCitations

Harrison's Principles of Internal Medicine.

Annals of Internal Medicine

1988

12.6K

Proposals for the Classification of the Acute Leukaemias F<scp>rench</scp>‐A<scp>merican</scp>‐B<scp>ritish</scp> (FAB) C<scp>o‐operative</scp> G<scp>roup</scp>

John M. Bennett, Daniel Catovsky, Marie‐Theregse Daniel,

British Journal of Haematology

1976

5.6K

Dose: A critical factor in cancer chemotherapy

Emil Frei, George P. Canellos

The American Journal of Medicine

1980

847

The Adult Respiratory Distress Syndrome

Thomas L. Petty, David G. Ashbaugh

CHEST Journal

1971

767

Arabinosyl Cytosine: A Useful Agent in the Treatment of Acute Leukemia in Adults

Rose Ruth Ellison, James F. Holland, Marise Weil,

Blood

1968

548

High-dose cytosine arabinoside therapy for refractory leukemia

RH Herzig, SN Wolff, HM Lazarus,

Blood

1983

369

High dose cytosine arabinoside (HDARAC) in refractory acute leukemia

Seth A. Rudnick, E Cadman, Robert L. Capizzi,

Cancer

1979

287

Cytidine Deaminase and the Development of Resistance to Arabinosyl Cytosine

C D Steuart, Philip J. Burke

Nature New Biology

1971

217

Dose schedule and antitumor studies of arabinosyl cytosine (NSC 63878).

Emil Frei, John N. Bickers, James S. Hewlett,

PubMed

1969

215

Central nervous system toxicity of high-dose systemic cytosine arabinoside

Hillard M. Lazarus, Roger H. Herzig, David J. Fishman,

Cancer

1981

205

Page 1